The generic version of Nucynta Er is anticipated to be available after September 22, 2028, following the expiration of the final patent, US8536130.
Nucynta Er is used for the management of neuropathic pain associated with diabetic peripheral neuropathy and relief of moderate to severe chronic pain. It can also be used for titrating an opioid to manage pain severe enough to require daily, long-term opioid treatment when alternative treatments are inadequate.
Nucynta Er holds a total of 9 patents. The last patent for Nucynta Er (US8536130) is set to expire on September 22, 2028, paving the way for Nucynta Er generics. Below are the details of the patents: